Sep 22, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Amgen ( AMGN ) Moves 3.5% Higher: Will This Strength Last?
Amgen (AMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Sep 19, 2025 • Benzinga
NEUTRAL
Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?' - Dynavax Technologies ( NASDAQ:DVAX ) , GSK ( NYSE:GSK )
Sen. Elizabeth Warren ( D-Mass. ) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps, rubella, and varicella or MMRV vaccine for children under 4 years old.
Aug 21, 2025 • Benzinga
NEUTRAL
Dynavax Says Investigational Shingles Vaccine At Par With GSK's Vaccine In Early-Stage Study - Dynavax Technologies ( NASDAQ:DVAX )
Z-1018 achieved 100% antibody response vs. Shingrix at 96.9% with fewer local and systemic reactions. Dynavax plans to test Z-1018 in adults 70+ in Part 2 of the Phase 1/2 trial starting in the second half of 2025. Get more market-moving news first with AI-powered analysis that turns noise into ...
Aug 07, 2025 • Motley Fool
SOMEWHAT-BULLISH
Dynavax ( DVAX ) Q2 Revenue Jumps 29%
Dynavax Technologies ( NASDAQ:DVAX ) , a biotechnology company focused on vaccines, released its results for the second quarter of 2025 on August 7, 2025. The company posted GAAP revenue of $95.4 million, sharply ahead of analyst expectations of $86.7 million, and GAAP diluted earnings per share ...
Aug 07, 2025 • Zacks Commentary
NEUTRAL
Dynavax Technologies ( DVAX ) Q2 Earnings and Revenues Beat Estimates
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of +16.67% and +8.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 06, 2025 • Zacks Commentary
NEUTRAL
Protagonist Therapeutics ( PTGX ) Reports Q2 Loss, Lags Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.77% and -46.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?